Silence Therapeutics PLC
Company Profile
Business description
Silence Therapeutics PLC is a biotechnology company focused on discovering and developing novel molecules incorporating short-interfering ribonucleic acid or siRNA. Using its mRNAi GOLD platform, the company has generated siRNA product candidates both for internal development pipeline as well as for out-licensed programs with third-party collaborators. Its wholly owned pipeline is focused on three therapeutic areas: cardiovascular disease, hematology, and rare diseases. The different product candidates in its pipeline are Divesiran (SLN124), a siRNA product candidate that has the potential to treat several hematological disorders; Zerlasiran (SLN360), being developed as a potential treatment to reduce cardiovascular issues; SLN-312; SLN-548; and multiple other programs.
Contact
72 Hammersmith Road
LondonW14 8TH
GBRT: +44 2034576900
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2025
Employees
116
Stocks News & Analysis
stocks
Ask the analyst: Can this genius product create the next ASX software king?
stocks
Impact of ANZ’s huge fine
stocks
Acquisition a sign of weakness for overvalued ASX share
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
---|---|---|---|
All Ordinaries | 9,151.20 | 1.30 | -0.01% |
CAC 40 | 7,886.26 | 10.67 | -0.14% |
DAX 40 | 23,675.76 | 73.10 | -0.31% |
Dow JONES (US) | 45,883.45 | 49.23 | 0.11% |
FTSE 100 | 9,255.73 | 21.30 | -0.23% |
HKSE | 26,438.51 | 8.05 | -0.03% |
NASDAQ | 22,348.75 | 207.64 | 0.94% |
Nikkei 225 | 44,902.27 | 134.15 | 0.30% |
NZX 50 Index | 13,234.89 | 26.58 | 0.20% |
S&P 500 | 6,615.28 | 30.99 | 0.47% |
S&P/ASX 200 | 8,877.70 | 3.00 | -0.03% |
SSE Composite Index | 3,861.86 | 1.36 | 0.04% |